{"protocolSection": {"identificationModule": {"nctId": "NCT01405508", "orgStudyIdInfo": {"id": "N01258"}, "secondaryIdInfos": [{"id": "2008-004714-27", "type": "EUDRACT_NUMBER"}], "organization": {"fullName": "UCB Pharma", "class": "INDUSTRY"}, "briefTitle": "Safety and Tolerability of Intravenous Brivaracetam (Infusion or Bolus) as Adjunctive Antiepileptic Therapy", "officialTitle": "A Multi-center, Open-label, Four-arm, Randomized Trial Evaluating the Safety and Tolerability of Brivaracetam Intravenous Infusion and Bolus, Administered in BID Regimen as an Adjunctive Antiepileptic Treatment in Subjects From 16 to 70 Years Suffering From Epilepsy"}, "statusModule": {"statusVerifiedDate": "2016-07", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": true, "nctId": "NCT03532516", "statusForNctId": "AVAILABLE"}, "startDateStruct": {"date": "2011-08"}, "primaryCompletionDateStruct": {"date": "2012-07", "type": "ACTUAL"}, "completionDateStruct": {"date": "2012-07", "type": "ACTUAL"}, "studyFirstSubmitDate": "2011-07-27", "studyFirstSubmitQcDate": "2011-07-28", "studyFirstPostDateStruct": {"date": "2011-07-29", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2016-03-14", "resultsFirstSubmitQcDate": "2016-03-14", "resultsFirstPostDateStruct": {"date": "2016-04-13", "type": "ESTIMATED"}, "dispFirstSubmitDate": "2013-06-03", "dispFirstSubmitQcDate": "2013-06-03", "dispFirstPostDateStruct": {"date": "2013-06-11", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2018-06-13", "lastUpdatePostDateStruct": {"date": "2018-07-11", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "UCB Pharma", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "This is a multicenter, open-label, 4-arm, randomized, parallel-group study to evaluate safety and tolerability of Brivaracetam Intravenous (BRV iv) as adjunctive treatment for adults with epilepsy according to an initiation or a conversion scheme, during repeated dosing (100 mg/administration twice daily for 4.5 days).", "detailedDescription": "Eligible subjects will be randomized in a 1:1:1:1 ratio to the 4 treatment arms"}, "conditionsModule": {"conditions": ["Epilepsy"], "keywords": ["N01258", "Brivaracetam", "Epilepsy", "IV", "intravenous"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 105, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Placebo tablets / Brivaracetam bolus", "type": "EXPERIMENTAL", "description": "Subjects will receive Placebo (PBO) tablets for one week followed by Brivaracetam (BRV) bolus for 4.5 days.\n\nDown-Titration:\n\n* If subject discontinues the study during the Run-In Period, then the subject will receive the treatment that he/she was assigned during Run-In\n* If subject discontinues during the Evaluation Period or after Day 12, the subject will receive Placebo tablets during Down-Titration:\n\nTablets will be provided for 4 weeks; 75 mg / intake BID for the first week, 50 mg / intake BID for the second week, 25 mg / intake BID for the third week, 10 mg / intake BID for the fourth week", "interventionNames": ["Drug: Brivaracetam bolus", "Other: Placebo"]}, {"label": "Brivaracetam (BRV) tablets / BRV bolus", "type": "EXPERIMENTAL", "description": "Subjects will receive Brivaracetam (BRV) tablets for one week followed by BRV bolus for 4.5 days.\n\nDown-Titration:\n\n* If subject discontinues the study during the Run-In Period, then the subject will receive the treatment that he/she was assigned during Run-In\n* If subject discontinues during the Evaluation Period or after Day 12, the subject will receive BRV tablets during Down-Titration:\n\nTablets will be provided for 4 weeks; 75 mg / intake BID for the first week, 50 mg / intake BID for the second week, 25 mg / intake BID for the third week, 10 mg / intake bid for the fourth week", "interventionNames": ["Drug: Brivaracetam tablets", "Drug: Brivaracetam bolus"]}, {"label": "Placebo tablets / Brivaracetam infusion", "type": "EXPERIMENTAL", "description": "Subjects will receive Placebo (PBO) tablets for one week followed by Brivaracetam (BRV) intravenous infusion for 4.5 days.\n\nDown-Titration:\n\n* If subject discontinues the study during the Run-In Period, then the subject will receive the treatment that he/she was assigned during Run-In\n* If subject discontinues during the Evaluation Period or after Day 12, the subject will receive BRV tablets during Down-Titration:\n\nTablets will be provided for 4 weeks; 75 mg / intake BID for the first week, 50 mg / intake BID for the second week, 25 mg / intake BID for the third week, 10 mg / intake BID for the fourth week", "interventionNames": ["Drug: Brivaracetam infusion", "Other: Placebo"]}, {"label": "Brivaracetam (BRV) tablets / BRV infusion", "type": "EXPERIMENTAL", "description": "Subjects will receive Brivaracetam (BRV) tablets for one week followed by Brivaracetam intravenous infusion for 4.5 days.\n\nDown-Titration:\n\n* If subject discontinues the study during the Run-In Period, then the subject will receive the treatment that he/she was assigned during Run-In\n* If subject discontinues during the Evaluation Period or after Day 12, the subject will receive BRV tablets during Down-Titration:\n\nTablets will be provided for 4 weeks; 75 mg / intake BID for the first week, 50 mg / intake BID for the second week, 25 mg / intake BID for the third week, 10 mg / intake BID for the fourth week", "interventionNames": ["Drug: Brivaracetam tablets", "Drug: Brivaracetam infusion"]}], "interventions": [{"type": "DRUG", "name": "Brivaracetam tablets", "description": "100 mg, intake twice daily (BID) for 7 days during Run-In Period", "armGroupLabels": ["Brivaracetam (BRV) tablets / BRV bolus", "Brivaracetam (BRV) tablets / BRV infusion"]}, {"type": "DRUG", "name": "Brivaracetam bolus", "description": "10 mL (= 100 mg) of Brivaracetam administered intravenously over 2 minutes twice daily (BID) during Evaluation Period", "armGroupLabels": ["Brivaracetam (BRV) tablets / BRV bolus", "Placebo tablets / Brivaracetam bolus"]}, {"type": "DRUG", "name": "Brivaracetam infusion", "description": "10 mL (= 100 mg) of Brivaracetam diluted in 90 mL 0.9 % isotonic saline sterile solution for intravenous administration infused over 15 minutes twice daily (BID) during Evaluation Period", "armGroupLabels": ["Brivaracetam (BRV) tablets / BRV infusion", "Placebo tablets / Brivaracetam infusion"]}, {"type": "OTHER", "name": "Placebo", "description": "100 mg twice daily (BID) for 7 days during Run-In Period", "armGroupLabels": ["Placebo tablets / Brivaracetam bolus", "Placebo tablets / Brivaracetam infusion"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Number of Subjects With at Least One Treatment-emergent Adverse Event During the Study (Maximum 40 Days)", "description": "An Adverse Event (AE) is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product.", "timeFrame": "40 days"}], "secondaryOutcomes": [{"measure": "Number of Subjects Who Withdrew Due to a Treatment-emergent Adverse Event During the Study (Maximum 40 Days)", "description": "An Adverse Event (AE) is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product.", "timeFrame": "40 days"}, {"measure": "Number of Subjects With at Least One Injection-related Treatment-emergent Adverse Event (TEAE) During the Evaluation Period.", "description": "An Adverse Event (AE) is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product.", "timeFrame": "4.5-day Evaluation Period"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* An Institutional Review Board/Independent Ethics Committee (IRB/IEC) approved written Informed Consent form signed and dated by the subject or by parent(s) or legal representative\n* Subjects from 16 to 70 years\n* Subjects with a body weight of \\>/= 40 kg\n* Female subjects without childbearing potential or female subjects with childbearing potential if they use a medically accepted contraceptive method\n* Subject/legal representative considered as reliable and capable of adhering to the protocol\n* Subjects with well-characterized focal or generalized epilepsy or epileptic syndrome\n* Subjects with a history of partial-onset seizures whether or not secondarily generalized or primary generalized seizures\n* Subjects being uncontrolled while treated with 1 to 2 permitted concomitant antiepileptic drugs (AEDs)\n* Permitted concomitant antiepileptic drugs (AEDs) and vagus nerve stimulation (VNS) being stable and at optimal dosage for the subject from at least 1 month before Visit 1 and expected to be kept stable during the Run-In and Evaluation Periods\n\nExclusion Criteria:\n\n* Mentally impaired subjects unable to understand the study purpose\n* History or presence of status epilepticus during 1 year preceding Visit 1 or Baseline\n* Subjects on felbamate with less than 18 months continuous exposure before Visit 1\n* Subjects currently on vigabatrin\n* Subject taking any drug with possible relevant central nervous system effects except is stable from at least 1 month before Visit 1 and expected to be kept stable during the trial\n* Subjects taking any drug that may significantly influence the metabolism of Brivaracetam (BRV) except if the dose has been kept stable at least 1 month before Visit 1, and is expected to be kept stable during the trial\n* History of cerebrovascular accident in the last 6 months\n* Subjects suffering from severe cardiovascular disease or peripheral vascular disease\n* Presence of any sign suggesting rapidly progressing brain disorder or brain tumor\n* Any clinical conditions which impair reliable participation in the study or necessitate the use of medication not allowed by protocol\n* Presence of a terminal illness\n* Presence of a serious infection\n* Subjects with a history of sever adverse hematologic reaction to any drug\n* Subjects suffering from severe disturbance of hemostasis\n* Impaired hepatic function: alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma-glutamyltransferase (GGT) values of more than 3 times the upper limit of the reference range\n* Subjects having clinically significant deviations from reference range values for laboratory parameters: creatinine clearance calculated \\< 50 ml / min, platelets \\< 100,000 / \u00b5L, or neutrophil cells \\< 1,800 / \u00b5L\n* Clinically significant electrocardiogram (ECG) abnormalities according to the Investigator\n* History of suicide attempt\n* In the Investigator's medical judgment, any current suicidal ideation or other serious psychiatric disorders requiring of having required hospitalization or medication\n* Known allergic reaction or intolerance to pyrrolidone derivatives and / or investigational product excipients\n* Known multiple drug allergies or severe drug allergy\n* Pregnant or lactating women\n* Known alcohol or drug addiction or abuse within the last 2 years\n* Subject institutionalized under judicial decision\n* Problems of venous accessibility\n* Subject taking part in another clinical / pharmacological study in the month preceding enrollment (Visit 1)\n* Investigators, coinvestigators, their spouses or children, or any study collaborators\n* Subjects previously treated with Brivaracetam (BRV)\n* Subject previously screened within this study", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "16 Years", "maximumAge": "70 Years", "stdAges": ["CHILD", "ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "UCB Clinical Trial Call Center", "affiliation": "+1 877 822 9493 (UCB)", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "001", "city": "Phoenix", "state": "Arizona", "country": "United States", "geoPoint": {"lat": 33.44838, "lon": -112.07404}}, {"facility": "775", "city": "Little Rock", "state": "Arkansas", "country": "United States", "geoPoint": {"lat": 34.74648, "lon": -92.28959}}, {"facility": "780", "city": "Lexington", "state": "Kentucky", "country": "United States", "geoPoint": {"lat": 37.98869, "lon": -84.47772}}, {"facility": "008", "city": "Bethesda", "state": "Maryland", "country": "United States", "geoPoint": {"lat": 38.98067, "lon": -77.10026}}, {"facility": "778", "city": "Columbus", "state": "Ohio", "country": "United States", "geoPoint": {"lat": 39.96118, "lon": -82.99879}}, {"facility": "776", "city": "Nashville", "state": "Tennessee", "country": "United States", "geoPoint": {"lat": 36.16589, "lon": -86.78444}}, {"facility": "777", "city": "Dallas", "state": "Texas", "country": "United States", "geoPoint": {"lat": 32.78306, "lon": -96.80667}}, {"facility": "036", "city": "Charlottesville", "state": "Virginia", "country": "United States", "geoPoint": {"lat": 38.02931, "lon": -78.47668}}, {"facility": "917", "city": "Brno", "country": "Czechia", "geoPoint": {"lat": 49.19522, "lon": 16.60796}}, {"facility": "915", "city": "Hradec Kralove", "country": "Czechia", "geoPoint": {"lat": 50.20923, "lon": 15.83277}}, {"facility": "916", "city": "Kromeriz", "country": "Czechia", "geoPoint": {"lat": 49.29785, "lon": 17.39312}}, {"facility": "913", "city": "Ostrava Poruba", "country": "Czechia", "geoPoint": {"lat": 49.83465, "lon": 18.28204}}, {"facility": "332", "city": "Bielefeld", "country": "Germany", "geoPoint": {"lat": 52.03333, "lon": 8.53333}}, {"facility": "903", "city": "Bonn", "country": "Germany", "geoPoint": {"lat": 50.73438, "lon": 7.09549}}, {"facility": "795", "city": "Katowice", "country": "Poland", "geoPoint": {"lat": 50.25841, "lon": 19.02754}}, {"facility": "479", "city": "Poznan", "country": "Poland", "geoPoint": {"lat": 52.40692, "lon": 16.92993}}, {"facility": "794", "city": "Warszawa", "country": "Poland", "geoPoint": {"lat": 52.22977, "lon": 21.01178}}]}, "referencesModule": {"references": [{"pmid": "33780735", "type": "DERIVED", "citation": "Toledo M, Brandt C, Quarato PP, Schulz AL, Cleveland JM, Wagener G, Klein P. Long-term safety, efficacy, and quality of life during adjunctive brivaracetam treatment in patients with uncontrolled epilepsy: An open-label follow-up trial. Epilepsy Behav. 2021 May;118:107897. doi: 10.1016/j.yebeh.2021.107897. Epub 2021 Mar 27."}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "Participant Flow refers to the Randomized Set (RS).", "recruitmentDetails": "This study started to recruit patients in August 2011 and concluded in July 2012.\n\n105 subjects were randomized to 4 different treatment groups.", "groups": [{"id": "FG000", "title": "Placebo Tablets / Brivaracetam Bolus", "description": "Subjects will receive Placebo (PBO) tablets for one week followed by Brivaracetam (BRV) bolus for 4.5 days.\n\nDown-Titration:\n\n* If subject discontinues the study during the Run-In Period, then the subject will receive the treatment that he/she was assigned during Run-In\n* If subject discontinues during the Evaluation Period or after Day 12, the subject will receive Placebo tablets during Down-Titration:\n\nTablets will be provided for 4 weeks; 75 mg / intake BID for the first week, 50 mg / intake BID for the second week, 25 mg / intake BID for the third week, 10 mg / intake BID for the fourth week"}, {"id": "FG001", "title": "Placebo Tablets / Brivaracetam Infusion", "description": "Subjects will receive Placebo (PBO) tablets for one week followed by Brivaracetam (BRV) intravenous infusion for 4.5 days.\n\nDown-Titration:\n\n* If subject discontinues the study during the Run-In Period, then the subject will receive the treatment that he/she was assigned during Run-In\n* If subject discontinues during the Evaluation Period or after Day 12, the subject will receive BRV tablets during Down-Titration:\n\nTablets will be provided for 4 weeks; 75 mg / intake BID for the first week, 50 mg / intake BID for the second week, 25 mg / intake BID for the third week, 10 mg / intake BID for the fourth week"}, {"id": "FG002", "title": "Brivaracetam (BRV) Tablets / BRV Bolus", "description": "Subjects will receive Brivaracetam (BRV) tablets for one week followed by BRV bolus for 4.5 days.\n\nDown-Titration:\n\n* If subject discontinues the study during the Run-In Period, then the subject will receive the treatment that he/she was assigned during Run-In\n* If subject discontinues during the Evaluation Period or after Day 12, the subject will receive BRV tablets during Down-Titration:\n\nTablets will be provided for 4 weeks; 75 mg / intake BID for the first week, 50 mg / intake BID for the second week, 25 mg / intake BID for the third week, 10 mg / intake bid for the fourth week"}, {"id": "FG003", "title": "Brivaracetam (BRV) Tablets / BRV Infusion", "description": "Subjects will receive Brivaracetam (BRV) tablets for one week followed by Brivaracetam intravenous infusion for 4.5 days.\n\nDown-Titration:\n\n* If subject discontinues the study during the Run-In Period, then the subject will receive the treatment that he/she was assigned during Run-In\n* If subject discontinues during the Evaluation Period or after Day 12, the subject will receive BRV tablets during Down-Titration:\n\nTablets will be provided for 4 weeks; 75 mg / intake BID for the first week, 50 mg / intake BID for the second week, 25 mg / intake BID for the third week, 10 mg / intake BID for the fourth week"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "26"}, {"groupId": "FG001", "numSubjects": "26"}, {"groupId": "FG002", "numSubjects": "27"}, {"groupId": "FG003", "numSubjects": "26"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "25"}, {"groupId": "FG001", "numSubjects": "25"}, {"groupId": "FG002", "numSubjects": "27"}, {"groupId": "FG003", "numSubjects": "26"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}]}], "dropWithdraws": [{"type": "AE, non-serious non-fatal", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"populationDescription": "Baseline Characetristics refer to the Safety Population consisting of all subjects who took at least 1 dose of study drug.", "groups": [{"id": "BG000", "title": "Placebo Tablets / Brivaracetam Bolus", "description": "Subjects will receive Placebo (PBO) tablets for one week followed by Brivaracetam (BRV) bolus for 4.5 days.\n\nDown-Titration:\n\n* If subject discontinues the study during the Run-In Period, then the subject will receive the treatment that he/she was assigned during Run-In\n* If subject discontinues during the Evaluation Period or after Day 12, the subject will receive Placebo tablets during Down-Titration:\n\nTablets will be provided for 4 weeks; 75 mg / intake BID for the first week, 50 mg / intake BID for the second week, 25 mg / intake BID for the third week, 10 mg / intake BID for the fourth week"}, {"id": "BG001", "title": "Placebo Tablets / Brivaracetam Infusion", "description": "Subjects will receive Placebo (PBO) tablets for one week followed by Brivaracetam (BRV) intravenous infusion for 4.5 days.\n\nDown-Titration:\n\n* If subject discontinues the study during the Run-In Period, then the subject will receive the treatment that he/she was assigned during Run-In\n* If subject discontinues during the Evaluation Period or after Day 12, the subject will receive BRV tablets during Down-Titration:\n\nTablets will be provided for 4 weeks; 75 mg / intake BID for the first week, 50 mg / intake BID for the second week, 25 mg / intake BID for the third week, 10 mg / intake BID for the fourth week"}, {"id": "BG002", "title": "Brivaracetam (BRV) Tablets / BRV Bolus", "description": "Subjects will receive Brivaracetam (BRV) tablets for one week followed by BRV bolus for 4.5 days.\n\nDown-Titration:\n\n* If subject discontinues the study during the Run-In Period, then the subject will receive the treatment that he/she was assigned during Run-In\n* If subject discontinues during the Evaluation Period or after Day 12, the subject will receive BRV tablets during Down-Titration:\n\nTablets will be provided for 4 weeks; 75 mg / intake BID for the first week, 50 mg / intake BID for the second week, 25 mg / intake BID for the third week, 10 mg / intake bid for the fourth week"}, {"id": "BG003", "title": "Brivaracetam (BRV) Tablets / BRV Infusion", "description": "Subjects will receive Brivaracetam (BRV) tablets for one week followed by Brivaracetam intravenous infusion for 4.5 days.\n\nDown-Titration:\n\n* If subject discontinues the study during the Run-In Period, then the subject will receive the treatment that he/she was assigned during Run-In\n* If subject discontinues during the Evaluation Period or after Day 12, the subject will receive BRV tablets during Down-Titration:\n\nTablets will be provided for 4 weeks; 75 mg / intake BID for the first week, 50 mg / intake BID for the second week, 25 mg / intake BID for the third week, 10 mg / intake BID for the fourth week"}, {"id": "BG004", "title": "Total Title"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "26"}, {"groupId": "BG001", "value": "26"}, {"groupId": "BG002", "value": "27"}, {"groupId": "BG003", "value": "26"}, {"groupId": "BG004", "value": "105"}]}], "measures": [{"title": "Age, Categorical", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "<=18 years", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "0"}]}, {"title": "Between 18 and 65 years", "measurements": [{"groupId": "BG000", "value": "26"}, {"groupId": "BG001", "value": "25"}, {"groupId": "BG002", "value": "27"}, {"groupId": "BG003", "value": "25"}, {"groupId": "BG004", "value": "103"}]}, {"title": ">=65 years", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "1"}, {"groupId": "BG004", "value": "2"}]}]}]}, {"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "40.6", "spread": "12.2"}, {"groupId": "BG001", "value": "39.5", "spread": "14.4"}, {"groupId": "BG002", "value": "42.0", "spread": "9.2"}, {"groupId": "BG003", "value": "44.4", "spread": "12.6"}, {"groupId": "BG004", "value": "41.6", "spread": "12.2"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "12"}, {"groupId": "BG001", "value": "10"}, {"groupId": "BG002", "value": "17"}, {"groupId": "BG003", "value": "17"}, {"groupId": "BG004", "value": "56"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "14"}, {"groupId": "BG001", "value": "16"}, {"groupId": "BG002", "value": "10"}, {"groupId": "BG003", "value": "9"}, {"groupId": "BG004", "value": "49"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Number of Subjects With at Least One Treatment-emergent Adverse Event During the Study (Maximum 40 Days)", "description": "An Adverse Event (AE) is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product.", "populationDescription": "Safety Population consisting of all subjects who took at least 1 dose of study drug.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "40 days", "groups": [{"id": "OG000", "title": "Placebo Tablets / Brivaracetam Bolus", "description": "Subjects will receive Placebo (PBO) tablets for one week followed by Brivaracetam (BRV) bolus for 4.5 days.\n\nDown-Titration:\n\n* If subject discontinues the study during the Run-In Period, then the subject will receive the treatment that he/she was assigned during Run-In\n* If subject discontinues during the Evaluation Period or after Day 12, the subject will receive Placebo tablets during Down-Titration:\n\nTablets will be provided for 4 weeks; 75 mg / intake BID for the first week, 50 mg / intake BID for the second week, 25 mg / intake BID for the third week, 10 mg / intake BID for the fourth week"}, {"id": "OG001", "title": "Placebo Tablets / Brivaracetam Infusion", "description": "Subjects will receive Placebo (PBO) tablets for one week followed by Brivaracetam (BRV) intravenous infusion for 4.5 days.\n\nDown-Titration:\n\n* If subject discontinues the study during the Run-In Period, then the subject will receive the treatment that he/she was assigned during Run-In\n* If subject discontinues during the Evaluation Period or after Day 12, the subject will receive BRV tablets during Down-Titration:\n\nTablets will be provided for 4 weeks; 75 mg / intake BID for the first week, 50 mg / intake BID for the second week, 25 mg / intake BID for the third week, 10 mg / intake BID for the fourth week"}, {"id": "OG002", "title": "Brivaracetam (BRV) Tablets / BRV Bolus", "description": "Subjects will receive Brivaracetam (BRV) tablets for one week followed by BRV bolus for 4.5 days.\n\nDown-Titration:\n\n* If subject discontinues the study during the Run-In Period, then the subject will receive the treatment that he/she was assigned during Run-In\n* If subject discontinues during the Evaluation Period or after Day 12, the subject will receive BRV tablets during Down-Titration:\n\nTablets will be provided for 4 weeks; 75 mg / intake BID for the first week, 50 mg / intake BID for the second week, 25 mg / intake BID for the third week, 10 mg / intake bid for the fourth week"}, {"id": "OG003", "title": "Brivaracetam (BRV) Tablets / BRV Infusion", "description": "Subjects will receive Brivaracetam (BRV) tablets for one week followed by Brivaracetam intravenous infusion for 4.5 days.\n\nDown-Titration:\n\n* If subject discontinues the study during the Run-In Period, then the subject will receive the treatment that he/she was assigned during Run-In\n* If subject discontinues during the Evaluation Period or after Day 12, the subject will receive BRV tablets during Down-Titration:\n\nTablets will be provided for 4 weeks; 75 mg / intake BID for the first week, 50 mg / intake BID for the second week, 25 mg / intake BID for the third week, 10 mg / intake BID for the fourth week"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "26"}, {"groupId": "OG001", "value": "26"}, {"groupId": "OG002", "value": "27"}, {"groupId": "OG003", "value": "26"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "20"}, {"groupId": "OG001", "value": "19"}, {"groupId": "OG002", "value": "21"}, {"groupId": "OG003", "value": "20"}]}]}]}, {"type": "SECONDARY", "title": "Number of Subjects Who Withdrew Due to a Treatment-emergent Adverse Event During the Study (Maximum 40 Days)", "description": "An Adverse Event (AE) is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product.", "populationDescription": "Safety Population consisting of all subjects who took at least 1 dose of study drug.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "40 days", "groups": [{"id": "OG000", "title": "Placebo Tablets / Brivaracetam Bolus", "description": "Subjects will receive Placebo (PBO) tablets for one week followed by Brivaracetam (BRV) bolus for 4.5 days.\n\nDown-Titration:\n\n* If subject discontinues the study during the Run-In Period, then the subject will receive the treatment that he/she was assigned during Run-In\n* If subject discontinues during the Evaluation Period or after Day 12, the subject will receive Placebo tablets during Down-Titration:\n\nTablets will be provided for 4 weeks; 75 mg / intake BID for the first week, 50 mg / intake BID for the second week, 25 mg / intake BID for the third week, 10 mg / intake BID for the fourth week"}, {"id": "OG001", "title": "Placebo Tablets / Brivaracetam Infusion", "description": "Subjects will receive Placebo (PBO) tablets for one week followed by Brivaracetam (BRV) intravenous infusion for 4.5 days.\n\nDown-Titration:\n\n* If subject discontinues the study during the Run-In Period, then the subject will receive the treatment that he/she was assigned during Run-In\n* If subject discontinues during the Evaluation Period or after Day 12, the subject will receive BRV tablets during Down-Titration:\n\nTablets will be provided for 4 weeks; 75 mg / intake BID for the first week, 50 mg / intake BID for the second week, 25 mg / intake BID for the third week, 10 mg / intake BID for the fourth week"}, {"id": "OG002", "title": "Brivaracetam (BRV) Tablets / BRV Bolus", "description": "Subjects will receive Brivaracetam (BRV) tablets for one week followed by BRV bolus for 4.5 days.\n\nDown-Titration:\n\n* If subject discontinues the study during the Run-In Period, then the subject will receive the treatment that he/she was assigned during Run-In\n* If subject discontinues during the Evaluation Period or after Day 12, the subject will receive BRV tablets during Down-Titration:\n\nTablets will be provided for 4 weeks; 75 mg / intake BID for the first week, 50 mg / intake BID for the second week, 25 mg / intake BID for the third week, 10 mg / intake bid for the fourth week"}, {"id": "OG003", "title": "Brivaracetam (BRV) Tablets / BRV Infusion", "description": "Subjects will receive Brivaracetam (BRV) tablets for one week followed by Brivaracetam intravenous infusion for 4.5 days.\n\nDown-Titration:\n\n* If subject discontinues the study during the Run-In Period, then the subject will receive the treatment that he/she was assigned during Run-In\n* If subject discontinues during the Evaluation Period or after Day 12, the subject will receive BRV tablets during Down-Titration:\n\nTablets will be provided for 4 weeks; 75 mg / intake BID for the first week, 50 mg / intake BID for the second week, 25 mg / intake BID for the third week, 10 mg / intake BID for the fourth week"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "26"}, {"groupId": "OG001", "value": "26"}, {"groupId": "OG002", "value": "27"}, {"groupId": "OG003", "value": "26"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "1"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}]}]}]}, {"type": "SECONDARY", "title": "Number of Subjects With at Least One Injection-related Treatment-emergent Adverse Event (TEAE) During the Evaluation Period.", "description": "An Adverse Event (AE) is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product.", "populationDescription": "Safety Population consisting of all subjects who took at least 1 dose of study drug.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "4.5-day Evaluation Period", "groups": [{"id": "OG000", "title": "Placebo Tablets / Brivaracetam Bolus", "description": "Subjects will receive Placebo (PBO) tablets for one week followed by Brivaracetam (BRV) bolus for 4.5 days.\n\nDown-Titration:\n\n* If subject discontinues the study during the Run-In Period, then the subject will receive the treatment that he/she was assigned during Run-In\n* If subject discontinues during the Evaluation Period or after Day 12, the subject will receive Placebo tablets during Down-Titration:\n\nTablets will be provided for 4 weeks; 75 mg / intake BID for the first week, 50 mg / intake BID for the second week, 25 mg / intake BID for the third week, 10 mg / intake BID for the fourth week"}, {"id": "OG001", "title": "Placebo Tablets / Brivaracetam Infusion", "description": "Subjects will receive Placebo (PBO) tablets for one week followed by Brivaracetam (BRV) intravenous infusion for 4.5 days.\n\nDown-Titration:\n\n* If subject discontinues the study during the Run-In Period, then the subject will receive the treatment that he/she was assigned during Run-In\n* If subject discontinues during the Evaluation Period or after Day 12, the subject will receive BRV tablets during Down-Titration:\n\nTablets will be provided for 4 weeks; 75 mg / intake BID for the first week, 50 mg / intake BID for the second week, 25 mg / intake BID for the third week, 10 mg / intake BID for the fourth week"}, {"id": "OG002", "title": "Brivaracetam (BRV) Tablets / BRV Bolus", "description": "Subjects will receive Brivaracetam (BRV) tablets for one week followed by BRV bolus for 4.5 days.\n\nDown-Titration:\n\n* If subject discontinues the study during the Run-In Period, then the subject will receive the treatment that he/she was assigned during Run-In\n* If subject discontinues during the Evaluation Period or after Day 12, the subject will receive BRV tablets during Down-Titration:\n\nTablets will be provided for 4 weeks; 75 mg / intake BID for the first week, 50 mg / intake BID for the second week, 25 mg / intake BID for the third week, 10 mg / intake bid for the fourth week"}, {"id": "OG003", "title": "Brivaracetam (BRV) Tablets / BRV Infusion", "description": "Subjects will receive Brivaracetam (BRV) tablets for one week followed by Brivaracetam intravenous infusion for 4.5 days.\n\nDown-Titration:\n\n* If subject discontinues the study during the Run-In Period, then the subject will receive the treatment that he/she was assigned during Run-In\n* If subject discontinues during the Evaluation Period or after Day 12, the subject will receive BRV tablets during Down-Titration:\n\nTablets will be provided for 4 weeks; 75 mg / intake BID for the first week, 50 mg / intake BID for the second week, 25 mg / intake BID for the third week, 10 mg / intake BID for the fourth week"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "26"}, {"groupId": "OG001", "value": "26"}, {"groupId": "OG002", "value": "27"}, {"groupId": "OG003", "value": "26"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "4"}, {"groupId": "OG003", "value": "3"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "Adverse Events were collected from Baseline over Run-In (Day 1) and Evaluation Period (Day 8 to Day 12) to the Safety Visit or Early Discontinuation Visit (up to 54 days).", "description": "Adverse Events refer to the Safety Population consisting of all subjects who took at least 1 dose of study drug.", "eventGroups": [{"id": "EG000", "title": "Placebo Tablets / Brivaracetam Bolus", "description": "Subjects will receive Placebo (PBO) tablets for one week followed by Brivaracetam (BRV) bolus for 4.5 days.\n\nDown-Titration:\n\n* If subject discontinues the study during the Run-In Period, then the subject will receive the treatment that he/she was assigned during Run-In\n* If subject discontinues during the Evaluation Period or after Day 12, the subject will receive Placebo tablets during Down-Titration:\n\nTablets will be provided for 4 weeks; 75 mg / intake BID for the first week, 50 mg / intake BID for the second week, 25 mg / intake BID for the third week, 10 mg / intake BID for the fourth week", "seriousNumAffected": 0, "seriousNumAtRisk": 26, "otherNumAffected": 17, "otherNumAtRisk": 26}, {"id": "EG001", "title": "Placebo Tablets / Brivaracetam Infusion", "description": "Subjects will receive Placebo (PBO) tablets for one week followed by Brivaracetam (BRV) intravenous infusion for 4.5 days.\n\nDown-Titration:\n\n* If subject discontinues the study during the Run-In Period, then the subject will receive the treatment that he/she was assigned during Run-In\n* If subject discontinues during the Evaluation Period or after Day 12, the subject will receive BRV tablets during Down-Titration:\n\nTablets will be provided for 4 weeks; 75 mg / intake BID for the first week, 50 mg / intake BID for the second week, 25 mg / intake BID for the third week, 10 mg / intake BID for the fourth week", "seriousNumAffected": 0, "seriousNumAtRisk": 26, "otherNumAffected": 15, "otherNumAtRisk": 26}, {"id": "EG002", "title": "Brivaracetam (BRV) Tablets / BRV Bolus", "description": "Subjects will receive Brivaracetam (BRV) tablets for one week followed by BRV bolus for 4.5 days.\n\nDown-Titration:\n\n* If subject discontinues the study during the Run-In Period, then the subject will receive the treatment that he/she was assigned during Run-In\n* If subject discontinues during the Evaluation Period or after Day 12, the subject will receive BRV tablets during Down-Titration:\n\nTablets will be provided for 4 weeks; 75 mg / intake BID for the first week, 50 mg / intake BID for the second week, 25 mg / intake BID for the third week, 10 mg / intake bid for the fourth week", "seriousNumAffected": 0, "seriousNumAtRisk": 27, "otherNumAffected": 15, "otherNumAtRisk": 27}, {"id": "EG003", "title": "Brivaracetam (BRV) Tablets / BRV Infusion", "description": "Subjects will receive Brivaracetam (BRV) tablets for one week followed by Brivaracetam intravenous infusion for 4.5 days.\n\nDown-Titration:\n\n* If subject discontinues the study during the Run-In Period, then the subject will receive the treatment that he/she was assigned during Run-In\n* If subject discontinues during the Evaluation Period or after Day 12, the subject will receive BRV tablets during Down-Titration:\n\nTablets will be provided for 4 weeks; 75 mg / intake BID for the first week, 50 mg / intake BID for the second week, 25 mg / intake BID for the third week, 10 mg / intake BID for the fourth week", "seriousNumAffected": 0, "seriousNumAtRisk": 26, "otherNumAffected": 14, "otherNumAtRisk": 26}], "otherEvents": [{"term": "Postural orthostatic tachycardia syndrome", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA15.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 26}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 26}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 27}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 26}]}, {"term": "Vertigo", "organSystem": "Ear and labyrinth disorders", "sourceVocabulary": "MedDRA15.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 26}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 26}, {"groupId": "EG002", "numEvents": 2, "numAffected": 2, "numAtRisk": 27}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 26}]}, {"term": "Dyspepsia", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA15.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 26}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 26}, {"groupId": "EG002", "numEvents": 2, "numAffected": 2, "numAtRisk": 27}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 26}]}, {"term": "Fatigue", "organSystem": "General disorders", "sourceVocabulary": "MedDRA15.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 26}, {"groupId": "EG001", "numEvents": 4, "numAffected": 2, "numAtRisk": 26}, {"groupId": "EG002", "numEvents": 4, "numAffected": 3, "numAtRisk": 27}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 26}]}, {"term": "Infusion site pain", "organSystem": "General disorders", "sourceVocabulary": "MedDRA15.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 26}, {"groupId": "EG001", "numEvents": 3, "numAffected": 3, "numAtRisk": 26}, {"groupId": "EG002", "numEvents": 2, "numAffected": 2, "numAtRisk": 27}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 26}]}, {"term": "Injection site erythema", "organSystem": "General disorders", "sourceVocabulary": "MedDRA15.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 26}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 26}, {"groupId": "EG002", "numEvents": 2, "numAffected": 2, "numAtRisk": 27}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 26}]}, {"term": "Injection site pain", "organSystem": "General disorders", "sourceVocabulary": "MedDRA15.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 26}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 26}, {"groupId": "EG002", "numEvents": 2, "numAffected": 2, "numAtRisk": 27}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 26}]}, {"term": "Somnolence", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA15.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 8, "numAffected": 8, "numAtRisk": 26}, {"groupId": "EG001", "numEvents": 7, "numAffected": 7, "numAtRisk": 26}, {"groupId": "EG002", "numEvents": 9, "numAffected": 7, "numAtRisk": 27}, {"groupId": "EG003", "numEvents": 10, "numAffected": 9, "numAtRisk": 26}]}, {"term": "Dizziness", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA15.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 4, "numAffected": 4, "numAtRisk": 26}, {"groupId": "EG001", "numEvents": 4, "numAffected": 4, "numAtRisk": 26}, {"groupId": "EG002", "numEvents": 3, "numAffected": 3, "numAtRisk": 27}, {"groupId": "EG003", "numEvents": 4, "numAffected": 4, "numAtRisk": 26}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA15.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 26}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 26}, {"groupId": "EG002", "numEvents": 3, "numAffected": 2, "numAtRisk": 27}, {"groupId": "EG003", "numEvents": 2, "numAffected": 2, "numAtRisk": 26}]}, {"term": "Dysgeusia", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA15.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 26}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 26}, {"groupId": "EG002", "numEvents": 2, "numAffected": 2, "numAtRisk": 27}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 26}]}, {"term": "Cough", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA15.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 26}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 26}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 27}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 26}]}, {"term": "Rash", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA15.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 3, "numAtRisk": 26}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 26}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 27}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 26}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "GT60", "restrictiveAgreement": true}, "pointOfContact": {"title": "UCB (Study Director)", "organization": "UCB Cares", "phone": "+1 887 822 9493"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24", "removedCountries": ["Czech Republic"]}, "conditionBrowseModule": {"meshes": [{"id": "D000004827", "term": "Epilepsy"}], "ancestors": [{"id": "D000001927", "term": "Brain Diseases"}, {"id": "D000002493", "term": "Central Nervous System Diseases"}, {"id": "D000009422", "term": "Nervous System Diseases"}], "browseLeaves": [{"id": "M7983", "name": "Epilepsy", "asFound": "Epilepsy", "relevance": "HIGH"}, {"id": "M5204", "name": "Brain Diseases", "relevance": "LOW"}, {"id": "M5742", "name": "Central Nervous System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC10", "name": "Nervous System Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "C000482793", "term": "Brivaracetam"}], "ancestors": [{"id": "D000000927", "term": "Anticonvulsants"}], "browseLeaves": [{"id": "M21860", "name": "Pharmaceutical Solutions", "relevance": "LOW"}, {"id": "M249745", "name": "Brivaracetam", "asFound": "Blood sugar", "relevance": "HIGH"}, {"id": "M4246", "name": "Anticonvulsants", "relevance": "LOW"}], "browseBranches": [{"abbrev": "PhSol", "name": "Pharmaceutical Solutions"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "AntiConv", "name": "Anticonvulsants"}]}}, "hasResults": true}